Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
In a year marked by significant volatility, CONMED Corporation (CNMD) stock has registered a new 52-week low, dipping to $50.34. According to InvestingPro analysis, the company appears undervalued at current levels, with a market capitalization of $1.56 billion and an attractive P/E ratio of 12. This latest price level reflects a stark contrast to the company’s performance over the past year, with CONMED experiencing a substantial 1-year change of -32.78%. Investors are closely monitoring the medical technology company as it navigates through a challenging market environment, which has seen many stocks retreat from their previous highs. The 52-week low serves as a critical indicator for shareholders and potential investors, who are now assessing CONMED’s long-term growth prospects and the potential for a rebound in its stock value. Notably, the company maintains strong fundamentals with a perfect Piotroski Score of 9 and has consistently paid dividends for 14 consecutive years. For deeper insights into CONMED’s valuation and growth potential, investors can access comprehensive analysis through InvestingPro, which offers additional ProTips and detailed financial metrics.
In other recent news, CONMED Corporation reported its fourth-quarter 2024 earnings, showing a 6.0% increase in organic revenue growth and surpassing consensus estimates. Despite ongoing supply chain challenges, the company improved its gross margin by 120 basis points and its operating margin by 280 basis points. However, CONMED’s revenue and EPS guidance for 2025 are below consensus due to these persistent supply chain issues. Needham maintained a Buy rating for CONMED but lowered its price target from $97 to $91, citing the company’s undervaluation. Meanwhile, JPMorgan downgraded CONMED from Overweight to Neutral, reducing the price target to $70, reflecting concerns over lower-than-expected 2025 earnings guidance. Stifel, on the other hand, retained its Buy rating and $72 price target, highlighting growth in CONMED’s Airseal system sales, which increased by 11.0% in 2024. Stifel’s analysis suggests that despite the introduction of competing technologies, CONMED’s Airseal product line continues to show growth potential. Additionally, CONMED announced the appointment of Mark Kaye to its Board of Directors, effective February 2025, bringing extensive experience in finance and healthcare.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.